Aurora Cannabis (21P) AI Stock Analysis

7 Followers

Aurora Cannabis

(Frankfurt:21P)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

International Medical GrowthInternational medical growth and rising geographic diversification strengthen Aurora’s revenue base beyond Canada. Greater exposure to regulated overseas markets, particularly Germany, can support durable demand, reduce reliance on one market, and provide a platform for further expansion.

Negative Factors

Revenue Contraction and LossesSharp TTM revenue contraction alongside renewed net and operating losses signals that the business has not yet established dependable scale economics. Persistent weakness in demand or mix can dilute fixed-cost absorption, limit reinvestment, and delay a durable return to profitability.

Aurora Cannabis (21P) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 332.01M
Dividend Yield: ―
Average Volume (3M): 4,686
Price to Earnings (P/E): -5.4
Beta (1Y): 0.87
Revenue Growth: -25.49%
EPS Growth: -32.41%
Country: Germany
Employees: 1,028
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Aurora Cannabis Business Overview & Revenue Model

Company Description

Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facil...

Aurora Cannabis Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q1-2027)|% Change Since:86.58%|Next Earnings Date:Nov 09, 2021

Earnings Call SentimentNeutral

The call presents a balanced picture: material short-term financial headwinds (notably a large year-over-year decline in adjusted EBITDA, lower adjusted net income, and negative free cash flow) driven largely by an external 30% reimbursement cut in Canadian medical. Offsetting these negatives are clear strategic strengths—17% international revenue growth to $43M, a 58% adjusted gross margin, strong cash position with no debt, an accretive EU GMP acquisition (Safari), genetics-driven production advantages (up to 40% yield improvement), and market leadership in several regulated international markets. Management frames FY2027 as a transitionary year with expected sequential improvement in Q2 and reiterated long-term targets (sustained double-digit growth and superior margins). Given the mix of significant near-term financial declines and pronounced strategic/operational positives, the overall tone is balanced.

Positive Updates

International Revenue Growth

International medical cannabis net revenue increased 17% year-over-year to $43.0 million, driven primarily by strong performance in Germany; 64% of total net revenue was generated outside Canada (up from 50% a year ago).

Negative Updates

Significant Adjusted EBITDA Decline

Adjusted EBITDA fell to $3.4 million from $10.8 million year-over-year, a decline of approximately 68.5%, reflecting lower adjusted gross profit before fair value adjustments.

Company Guidance

Management reaffirmed fiscal 2027 outlook while noting Q2 revenue and adjusted EBITDA are expected to be substantially higher than Q1; Q1 results included net revenue of $67.6M (international medical revenue +17% to $43M), ~64% of revenue generated outside Canada (vs. 50% a year ago), adjusted gross margin of 58% (at the high end of the annual range), adjusted EBITDA of $3.4M (vs. $10.8M prior year), adjusted net income of $3.8M (vs. $6.6M), consolidated adjusted SG&A of $35.1M (down from $36.1M), free cash flow outflow of $5.8M (vs. inflow $6.8M), nearly $150M in cash, cash equivalents and short-term investments with no debt, and an expected industry headwind from a 30% VAC reimbursement cut effective April 1; they also said the Safari acquisition (59,000 sq ft EU‑GMP facility) was accretive in Q1, genetics can drive up to a 40% yield improvement, and longer‑term targets remain sustained double‑digit revenue growth, superior margins and higher EBITDA contributions.

Aurora Cannabis Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:21P against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:CRON	83Outperform	CAD 1.78B	21.51	5.35%	―	54.74%	60.60%
TSE:GTII	69Neutral	CAD 2.05B	15.49	5.30%	―	6.44%	127.50%
TSE:CURA	52Neutral	CAD 3.37B	-245.71	-1.47%	―	5.01%	92.12%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:WEED	46Neutral	CAD 377.68M	-1.32	-29.85%	―	10.67%	74.14%

* Healthcare Sector Average

Performance Comparison

DE:21P and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:21P	Aurora Cannabis (US)	4.56	0.76	20.00%
TSE:WEED	Canopy Growth	0.88	-0.65	-42.48%
TSE:CRON	Cronos Group (US)	4.93	1.44	41.26%
TSE:CURA	Curaleaf Holdings (Otc)	12.69	1.86	17.17%
TSE:GTII	Green Thumb Industries (OTC)	9.37	0.08	0.86%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Aurora Cannabis AI Stock Analysis